Lack of activity of docetaxel in soft tissue sarcomas: Results of a phase II study of the Italian Group on Rare Tumors

Armando Santoro, Antonella Romanini, Alberto Rosso, Sergio Frustaci, Alessandro Comandone, Gaetano Apice, Domenico De Toma, Luigi Dogliotti, Rita Lionetto, Carla Dani, Paolo Bruzzi, Marco Piolini, Paola Bergnolo, Claudio Verusio

Research output: Contribution to journalArticle

Abstract

Purpose. The prognosis of advanced soft tissue sarcoma is poor, only a few drugs showing some activity with response rates around 15-25%. Consequently drug development seems mandatory to improve treatment outcome. Following previous favourable EORTC experience, the Italian Group on Rare Tumors started a phase II study with docetaxel to confirm the activity of this drug in soft tissue sarcoma. Patients and methods. Thirty-seven patients with soft tissue sarcoma resistant to at least one anthracycline-containing regimen were enrolled in a phase II multicenter study evaluating docetaxel 100 mg/m2 in a 1-h i.v. infusion q3 weeks. Results. Thirty-seven patients were enrolled onto this phase II study and 36 were evaluable for response. Only one partial remission was observed [2.8% with 95% confidence interval (CI) 0.1-16.2%]. Median progression-free and overall survival were 42 and 350 days, respectively. Neutropenia and leukopenia as well as cutaneous manifestations were the most common toxicities. Discussion. The results of this phase II study do not confirm a previous EORTC report on the activity of docetaxel in soft tissue sarcoma, but are consistent with other more recent phase II studies. The accumulated evidence does not justify the use of this drug in the management of patients suffering from this disease, resistant to anthracycline-containing regimens.

Original languageEnglish
Pages (from-to)177-181
Number of pages5
JournalSarcoma
Volume3
Issue number3-4
Publication statusPublished - 1999

Fingerprint

docetaxel
Sarcoma
Anthracyclines
Pharmaceutical Preparations
Neoplasms
Skin Manifestations
Leukopenia
Neutropenia
Multicenter Studies
Disease-Free Survival
Confidence Intervals

Keywords

  • Docetaxel
  • Soft tissue sarcoma

ASJC Scopus subject areas

  • Oncology

Cite this

Santoro, A., Romanini, A., Rosso, A., Frustaci, S., Comandone, A., Apice, G., ... Verusio, C. (1999). Lack of activity of docetaxel in soft tissue sarcomas: Results of a phase II study of the Italian Group on Rare Tumors. Sarcoma, 3(3-4), 177-181.

Lack of activity of docetaxel in soft tissue sarcomas : Results of a phase II study of the Italian Group on Rare Tumors. / Santoro, Armando; Romanini, Antonella; Rosso, Alberto; Frustaci, Sergio; Comandone, Alessandro; Apice, Gaetano; De Toma, Domenico; Dogliotti, Luigi; Lionetto, Rita; Dani, Carla; Bruzzi, Paolo; Piolini, Marco; Bergnolo, Paola; Verusio, Claudio.

In: Sarcoma, Vol. 3, No. 3-4, 1999, p. 177-181.

Research output: Contribution to journalArticle

Santoro, A, Romanini, A, Rosso, A, Frustaci, S, Comandone, A, Apice, G, De Toma, D, Dogliotti, L, Lionetto, R, Dani, C, Bruzzi, P, Piolini, M, Bergnolo, P & Verusio, C 1999, 'Lack of activity of docetaxel in soft tissue sarcomas: Results of a phase II study of the Italian Group on Rare Tumors', Sarcoma, vol. 3, no. 3-4, pp. 177-181.
Santoro, Armando ; Romanini, Antonella ; Rosso, Alberto ; Frustaci, Sergio ; Comandone, Alessandro ; Apice, Gaetano ; De Toma, Domenico ; Dogliotti, Luigi ; Lionetto, Rita ; Dani, Carla ; Bruzzi, Paolo ; Piolini, Marco ; Bergnolo, Paola ; Verusio, Claudio. / Lack of activity of docetaxel in soft tissue sarcomas : Results of a phase II study of the Italian Group on Rare Tumors. In: Sarcoma. 1999 ; Vol. 3, No. 3-4. pp. 177-181.
@article{298974c5f95d4aee9670cd2ff6e24441,
title = "Lack of activity of docetaxel in soft tissue sarcomas: Results of a phase II study of the Italian Group on Rare Tumors",
abstract = "Purpose. The prognosis of advanced soft tissue sarcoma is poor, only a few drugs showing some activity with response rates around 15-25{\%}. Consequently drug development seems mandatory to improve treatment outcome. Following previous favourable EORTC experience, the Italian Group on Rare Tumors started a phase II study with docetaxel to confirm the activity of this drug in soft tissue sarcoma. Patients and methods. Thirty-seven patients with soft tissue sarcoma resistant to at least one anthracycline-containing regimen were enrolled in a phase II multicenter study evaluating docetaxel 100 mg/m2 in a 1-h i.v. infusion q3 weeks. Results. Thirty-seven patients were enrolled onto this phase II study and 36 were evaluable for response. Only one partial remission was observed [2.8{\%} with 95{\%} confidence interval (CI) 0.1-16.2{\%}]. Median progression-free and overall survival were 42 and 350 days, respectively. Neutropenia and leukopenia as well as cutaneous manifestations were the most common toxicities. Discussion. The results of this phase II study do not confirm a previous EORTC report on the activity of docetaxel in soft tissue sarcoma, but are consistent with other more recent phase II studies. The accumulated evidence does not justify the use of this drug in the management of patients suffering from this disease, resistant to anthracycline-containing regimens.",
keywords = "Docetaxel, Soft tissue sarcoma",
author = "Armando Santoro and Antonella Romanini and Alberto Rosso and Sergio Frustaci and Alessandro Comandone and Gaetano Apice and {De Toma}, Domenico and Luigi Dogliotti and Rita Lionetto and Carla Dani and Paolo Bruzzi and Marco Piolini and Paola Bergnolo and Claudio Verusio",
year = "1999",
language = "English",
volume = "3",
pages = "177--181",
journal = "Sarcoma",
issn = "1357-714X",
publisher = "Hindawi Publishing Corporation",
number = "3-4",

}

TY - JOUR

T1 - Lack of activity of docetaxel in soft tissue sarcomas

T2 - Results of a phase II study of the Italian Group on Rare Tumors

AU - Santoro, Armando

AU - Romanini, Antonella

AU - Rosso, Alberto

AU - Frustaci, Sergio

AU - Comandone, Alessandro

AU - Apice, Gaetano

AU - De Toma, Domenico

AU - Dogliotti, Luigi

AU - Lionetto, Rita

AU - Dani, Carla

AU - Bruzzi, Paolo

AU - Piolini, Marco

AU - Bergnolo, Paola

AU - Verusio, Claudio

PY - 1999

Y1 - 1999

N2 - Purpose. The prognosis of advanced soft tissue sarcoma is poor, only a few drugs showing some activity with response rates around 15-25%. Consequently drug development seems mandatory to improve treatment outcome. Following previous favourable EORTC experience, the Italian Group on Rare Tumors started a phase II study with docetaxel to confirm the activity of this drug in soft tissue sarcoma. Patients and methods. Thirty-seven patients with soft tissue sarcoma resistant to at least one anthracycline-containing regimen were enrolled in a phase II multicenter study evaluating docetaxel 100 mg/m2 in a 1-h i.v. infusion q3 weeks. Results. Thirty-seven patients were enrolled onto this phase II study and 36 were evaluable for response. Only one partial remission was observed [2.8% with 95% confidence interval (CI) 0.1-16.2%]. Median progression-free and overall survival were 42 and 350 days, respectively. Neutropenia and leukopenia as well as cutaneous manifestations were the most common toxicities. Discussion. The results of this phase II study do not confirm a previous EORTC report on the activity of docetaxel in soft tissue sarcoma, but are consistent with other more recent phase II studies. The accumulated evidence does not justify the use of this drug in the management of patients suffering from this disease, resistant to anthracycline-containing regimens.

AB - Purpose. The prognosis of advanced soft tissue sarcoma is poor, only a few drugs showing some activity with response rates around 15-25%. Consequently drug development seems mandatory to improve treatment outcome. Following previous favourable EORTC experience, the Italian Group on Rare Tumors started a phase II study with docetaxel to confirm the activity of this drug in soft tissue sarcoma. Patients and methods. Thirty-seven patients with soft tissue sarcoma resistant to at least one anthracycline-containing regimen were enrolled in a phase II multicenter study evaluating docetaxel 100 mg/m2 in a 1-h i.v. infusion q3 weeks. Results. Thirty-seven patients were enrolled onto this phase II study and 36 were evaluable for response. Only one partial remission was observed [2.8% with 95% confidence interval (CI) 0.1-16.2%]. Median progression-free and overall survival were 42 and 350 days, respectively. Neutropenia and leukopenia as well as cutaneous manifestations were the most common toxicities. Discussion. The results of this phase II study do not confirm a previous EORTC report on the activity of docetaxel in soft tissue sarcoma, but are consistent with other more recent phase II studies. The accumulated evidence does not justify the use of this drug in the management of patients suffering from this disease, resistant to anthracycline-containing regimens.

KW - Docetaxel

KW - Soft tissue sarcoma

UR - http://www.scopus.com/inward/record.url?scp=0033509218&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033509218&partnerID=8YFLogxK

M3 - Article

C2 - 18521282

AN - SCOPUS:0033509218

VL - 3

SP - 177

EP - 181

JO - Sarcoma

JF - Sarcoma

SN - 1357-714X

IS - 3-4

ER -